Josh Doll, MD
Interventional Cardiology · Greenville, SCNPI 1609972603
Payments from drug & device makers
Across 495 payments — averaging $866.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$267K
- E.r. Squibb & Sons, L.L.C.$154K
- Edwards Lifesciences$3K
- Abiomed$1K
- Boston Scientific$819
- Medtronic$620
- plus $3K from 32 others
Across 1 payment — averaging $17.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Circulation Inc$18
What the payments were for
- Consulting fees$8,35011%
- Speaking & faculty fees$54,10769%
- Travel & lodging$3,8775%
- Food & beverage$12,36016%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 100 | $266,587 |
| E.r. Squibb & Sons, L.L.C. | 87 | $153,557 |
| Edwards Lifesciences | 90 | $2,757 |
| Abiomed | 30 | $1,011 |
| Boston Scientific | 20 | $819 |
| Medtronic(2 entities) | 43 | $620 |
| Bristol Myers Squibb(2 entities) | 2 | $573 |
| Novartis | 21 | $390 |
| Inari Medical, Inc. | 6 | $333 |
| Atricure, Inc. | 13 | $317 |
| AstraZeneca | 6 | $187 |
| Shockwave Medical, Inc | 4 | $181 |
| Amgen | 8 | $144 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $118 |
| Boehringer Ingelheim | 6 | $109 |
| Johnson & Johnson(2 entities) | 7 | $106 |
| Cvrx, Inc. | 6 | $105 |
| Terumo Medical Corporation | 4 | $104 |
| Philips North America LLC | 5 | $100 |
| United Therapeutics Corporation | 1 | $100 |
| Alnylam Pharmaceuticals Inc. | 4 | $81 |
| Kestra Medical Technology Services, Inc. | 2 | $48 |
| Cardiva Medical, Inc. | 3 | $46 |
| Cardiovascular Systems Inc. | 3 | $40 |
| Biosense Webster, Inc. | 1 | $38 |
| Pfizer | 2 | $36 |
| Chiesi USA, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Convatec Inc. | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Penumbra, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Bayer | 1 | $18 |
| AbbVie | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Angiodynamics, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$59,491
- Impella$405
- WATCHMAN FLX$284
- SAPIEN 3 Ultra RESILIA$279
- EVOQUE$203
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$186
- Diamondback Coronary$167
- FlowTriever$162
- ClotTriever$162
- Dragonfly OCT$157
- Mitra Clip system$147
- Xience Sierra Coronary Stent System$141
- SYNERGY$121
- ELIQUIS$118
- FARXIGA$118
- Allure Quadra RF CRT Pacemaker$110
- Edwards SAPIEN 3 Transcatheter Heart Valve$110
How this compares
$428,744 in reported general payments places this provider in the 90th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 133 | $1,081,412 |
| EliquisApixaban | 211 | $250,621 |
| Repatha SureclickEvolocumab | 53 | $60,008 |
| EntrestoSacubitril/Valsartan | 54 | $52,364 |
| XareltoRivaroxaban | 46 | $46,259 |
| Praluent PenAlirocumab | 32 | $30,602 |
| Repatha PushtronexEvolocumab | 19 | $24,557 |
| JardianceEmpagliflozin | 14 | $14,986 |
| BrilintaTicagrelor | 11 | $11,015 |
| Icosapent Ethyl | 13 | $3,967 |
| Metoprolol Succinate | 280 | $3,880 |
| Rosuvastatin Calcium | 188 | $2,891 |
| Atorvastatin Calcium | 226 | $2,305 |
| Ezetimibe | 61 | $2,252 |
| Ranolazine ErRanolazine | 11 | $2,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $153,557 | $1,081,412133 claims |
| PfizerEliquis | $36 | $250,621211 claims |
| NovartisEntresto | $390 | $52,36454 claims |
| Johnson & JohnsonXarelto | $106 | $46,25946 claims |
| Boehringer IngelheimJardiance | $109 | $14,98614 claims |
| AstraZenecaBrilinta | $187 | $11,01511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Greenville
- Daniel GreenGreenville$256K
- Jesse JorgensenGreenville$197K
- Chetan PatelGreenville$104K
- Dominic JohnsonGreenville$13K
- David ManlyGreenville$11K
- Daniel SteinbergCharleston$1.1M
- Nicholas AmorosoPawleys Island$1.1M
- Robert LeonardiWest Columbia$881K
- Lars RunquistCharleston$861K
- Kurt BarringhausColumbia$536K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.